関連する実験動画

Updated: Sep 9, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

クエルセチンは,腸内微生物群によるイソヴァニル酸の産生を促進し,腸内バリア機能を強化することで大腸炎を緩和する

Liang Lei^1,2, Jing Wang³, Juanjuan Wang³

¹Central Laboratory, Wuhan Fourth Hospital, Wuhan, China.

Current research in food science

|September 5, 2025

まとめ

クエルセチンは,腸内微生物のイソヴァニル酸 (IVA) 産生を刺激し,腸内バリア機能を強化することで,潰瘍性大腸炎 (UC) を緩和します. この研究は,腸内微生物群-IVA-腸内障壁軸がクエルセチンの鍵であることを示しています.

科学分野:

胃腸内科
微生物学
薬理学について

背景:

潰瘍性大腸炎 (UC) は慢性炎症性腸疾患で,治療の選択肢は限られている.
腸内微生物の不活性化と腸内バリア機能の障害はUCの特徴です.
植物性フラボノイドであるクエルセチンは,抗炎症性および微生物群調節性を持つが,UCにおけるそのメカニズムは不明である.

研究の目的:

クエルセチンの抗大腸炎作用における腸内微生物群-イソバニル酸 (IVA) -腸内障壁軸の役割を調査する.
クエルセチンが腸内微生物群を調節してIVAを生成し,UCにおける腸内バリア機能を改善する方法を明らかにする.

主な方法:

腸内微生物の組成を分析するために 16S rDNAの配列を決定する.
イソバニル酸 (IVA) レベルを定量化するための代謝学.
IVAサプリメントと併用して,大腸炎モデルでクエルセチンと抗生物質 (ABX) を投与する.

主要な成果:

クエルセチンの治療は,腸内微生物群を調節することによってIVAの産生を増加させ,特に*Clostridium_XIVa*と*Clostridium_XI*を増加させた.
抗生物質による腸内微生物の減少は,IVAレベルを低下させ,大腸炎に対するクエルセチンの有益な効果を廃止しました.
IVAサプリメントだけで大腸炎を和らげ,腸のバリア機能を強化し,クエルセチンの効果を模倣した.

結論:

腸内微生物群に由来するIVAは,潰瘍性大腸炎におけるクエルセチンの治療効果に不可欠です.
腸内微生物群 - IVA - 腸内バリア軸はUCの新たな治療目標です.
クエルセチンとIVAは,大腸炎やその他の腸炎症の治療薬として潜在性を示しています.

キーワード:

腸のバリア機能腸内細菌イソバニル酸 (IVA)クエルセチン潰瘍性大腸炎

さらに関連する動画

Quantification of Violacein in Chromobacterium violaceum and Its Inhibition by Bioactive Compounds

Quantification of Violacein in Chromobacterium violaceum and Its Inhibition by Bioactive Compounds

Published on: August 8, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

関連する概念動画

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...